Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. We did a systematic review of randomise... D Yahav,M Paul,A Fraser,... - 《Lancet Infectious Diseases》 被引量: 354发表: 2007年 Pharmacodynamics of once-daily amikacin in various...
Cefepime is a broad-spectrum fourth-generation cephalosporin with activity against both gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa. Cefepime is most commonly used for urinary tract infections, soft tissue infections, and febrile neutropenia. Cefepime does not work against inf...
Broad spectrum Gram-positive and Gram-negative organisms (building on Third Generation Cephalosporin coverage) Beta-Lactamase resistant organisms More AmpB beta lactamase resistant than second and Third Generation Cephalosporins Better activity against Citrobacter and Enterobacter Pseudomonas coverage (similar to...
Cefepime, a potent cephalosporin belonging to the beta-lactam class of antibiotics, addresses a spectrum of bacterial infections caused by gram-negative and gram-positive organisms. Cefepime's efficacy is validated by FDA approval for conditions including pneumonia, complicated and uncomplicated urinary tr...
Efficacy and safety of cefepime: a systematic review and meta-analysis Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. We did a systematic review of randomise... D Yahav,M Paul,A Fraser,... - 《Lancet Infectious Diseases》 被...
Cefepime is a semi-synthetic fourth generation cephalosporin with broader Gram-positive and excellent Gram-negative bacterial coverage. Its extended anti-microbial activity and infrequent tendency to develop resistance makes it popular for treatment of infections due to multi-drug resistant organisms. It ...
As up to 80% of OXA-48-like positive isolates coproduce extended-spectrum β-lactamases, a combination of β-lactams with broad-spectrum β-lactamase inhibitors is required to counteract all OXA-48-producing strains effectively. Herein, we evaluated the activity of cefepime-taniborbactam against ...
On the other hand, if one postulates an MIC of 8 mg/l, which was associated with treatment failures in patients with bacteremia due to Gram negative pathogens [6], then close to 50% of the patients would have had an inappropriate coverage (T>MIC > 50%). This is of particular concern...
Methods: A prospective pilot study was conducted utilizing daptomycin (6 mg/kg IV q 24 hours) and cefepime for moderate to high-risk febrile neutropenic patients with increased risk of gram-positive infections. Eleven patients (10 male, 1 female) were enrolled, ages 40–82 yrs (mean = 58)...
Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria. We did a systematic review of randomise... D Yahav,M Paul,A Fraser,... - 《Lancet Infectious Diseases》 被引量: 354发表: 2007年 Low plasma cefepime levels in critically ill sep...